Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases 2017. An Official American Thoracic Society Workshop Report

Ryan AL., Ikonomou L., Atarod S., Bölükbas DA., Collins J., Freishtat R.

Prospective Study on Systemic / IV, published in Am J Respir Cell Mol Biol (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Am J Respir Cell Mol Biol (2019)
Reported sample size
—
Source database
Europe PMC
PMID
31573338
PMCID
PMC6775946
DOI
10.1165/rcmb.2019-0286st
Citations
9

Abstract (original English)

The University of Vermont Larner College of Medicine, in collaboration with the National Heart, Lung, and Blood Institute (NHLBI), the Alpha-1 Foundation, the American Thoracic Society, the Cystic Fibrosis Foundation, the European Respiratory Society, the International Society for Cell & Gene Therapy, and the Pulmonary Fibrosis Foundation, convened a workshop titled "Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases" from July 24 through 27, 2017, at the University of Vermont, Burlington, Vermont. The conference objectives were to review and discuss current understanding of the following topics: 1 ) stem and progenitor cell biology and the role that they play in endogenous repair or as cell therapies after lung injury, 2 ) the emerging role of extracellular vesicles as potential therapies, 3 ) ex vivo bioengineering of lung and airway tissue, and 4 ) progress in induced pluripotent stem cell protocols for deriving lung cell types and applications in disease modeling. All of these topics are research areas in which significant and exciting progress has been made over the past few years. In addition, issues surrounding the ethics and regulation of cell therapies worldwide were discussed, with a special emphasis on combating the growing problem of unproven cell interventions being administered to patients with lung diseases. Finally, future research direc

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
LungStem CellsHumansLung DiseasesTissue EngineeringResearchForecastingHealth PrioritiesClinical Trials as TopicStem Cell Niche

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research